We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
GINA
BROWN
giclinicaltrials@imperial.ac.uk
Sokol
Shala
sokol.shala@nihr.ac.uk
CAROLINE
MARTIN
c.martin1@imperial.ac.uk
GINA
BROWN
gina.brown@imperial.ac.uk
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
After patients receive preoperative treatment for locally advanced rectal cancer, MRI scans are performed. Currently the MRI scan reading is not used to make decisions about further treatment plans. This trial will test if viewing the MRI scans in a different way, that we have developed and will teach to other radiologist, it is possible to assess how the tumour has responded to treatment. This technique is called the ‘mrTRG’ (MRI Tumour Regression Grade). We plan to offer watch and wait according to the mrTRG.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Drug;Imaging;Active Monitoring;
You can take part if:
You may not be able to take part if:
1) Have metastatic disease (including resectable liver metastases) 2) Are contraindicated for MRI eg. non-mr compatable hip prosthesis, cardiac pacemaker 3) Are scheduled to receive less than 45Gy or more than 55Gy long course radiotherapy 4) Are contraindicated for chemoradiotherapy (CRT) or systemic chemotherapy 5) Are receiving or planned to receive treatment outside of that stipulated by the protocol,such as an alternative cytotoxic or investigational drug. 6) Are pregnant, breastfeeding or unable / unwilling to comply with pregnancy prevention guidelines 7) Any other malignant disease within the preceding 5 years with the exception of non-melanomatous skin cancer, carcinoma in situ and early stage disease with <5% recurrence risk
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
GINA
BROWN
giclinicaltrials@imperial.ac.uk
GINA
BROWN
gina.brown@imperial.ac.uk
CAROLINE
MARTIN
c.martin1@imperial.ac.uk
Sokol
Shala
sokol.shala@nihr.ac.uk
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by PELICAN CANCER FOUNDATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 20576
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
